tbuckley/cabot-search huggingface dataset:
<i>EGFR</i>-Mutated Lung Cancer With<i>T790M</i>-Acquired Resistance in the Brain and Histologic Transformation in the Lung
Authors: Kevin S. Scher, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky, Karen L. Reckamp
Journal: Journal of the National Comprehensive Cancer Network (2013)

This case report describes the rare occurrence of a T790M resistance mutation found in a central nervous system (CNS) parenchymal metastasis. A concomitant squamous histology transformation in a lung non-T790M-resistant metastasis is also described. The authors hypothesize that this CNS resistance and histology transformation may have resulted from intermittent use of erlotinib treatment. This case report emphasizes the complexities of using erlotinib in the induction setting.
Abstract 11583: Length of Hospital Stay and All-Cause Mortality Among Adults With Atrial Fibrillation Hospitalized for Bleeding During Treatment With Warfarin, Dabigatran, or Rivaroxaban
Authors: Blake Charlton, Gboyega Adeboyeje, John J Barron, Deborah Grady, Jaekyu Shin, Rita Redberg
Journal: Circulation (2015)

Introduction: Little is known about the relative outcomes of bleeding complications during warfarin therapy compared to bleeding complications during treatment with dabigatran or rivaroxaban. Hypothesis: Because warfarin is more easily reversible, bleeding complications during warfarin therapy may be associated with better outcomes. Methods: We performed a retrospective cohort study using a US commercial claims database of 38 million members from 11/1/10 to 3/31/14. Participants were adults with atrial fibrillation hospitalized for bleeding after starting warfarin, dabigatran, or rivaroxaban. The outcomes were length of hospital stay, ICU admission, length of ICU stay, and all-cause mortality. The analyses used propensity scores as covariates in a multivariable Poisson regression. Subgroup analyses examined patients with chronic kidney disease, heart failure, more than 7 comorbidities, hemorrhagic stroke, major gastrointestinal bleed, those over 75, those without ICU admission, and those restarting anticoagulation after discharge. Results: Admissions for bleeding included 2446 warfarin, 442 dabigatran, and 256 rivaroxaban users. Warfarin users were older than dabigatran or rivaroxaban users (74 vs 69 vs 68 years) and had more comorbidities. After adjustment, warfarin was associated with a 2.2 mean day increase in hospital stay (CI 2.0 - 2.5) compared to dabigatran and a 3.1 mean day increase (CI 2.8 - 3.4) compared to rivaroxaban. There were no significant differences in the proportions of ICU admissions among the 3 groups. Warfarin was associated with a mean ICU stay increase of 2.3 days (CI 0.94 - 3.6) compared to dabigatran. After 3.4 years follow up, there was a 17% adjusted mortality in the warfarin cohort, 13% in the dabigatran cohort, and 6% in the rivaroxaban cohort. Warfarin was associated with longer hospitalization in every subgroup. Conclusions: Despite warfarin’s reversibility, bleeding complications during warfarin therapy are associated with longer hospitalization and higher adjusted mortality. However, because patients treated with newer oral anticoagulants are younger and healthier, randomized trials are necessary to better understand these unexpected differences in bleeding-related outcomes.
A Quantitative Dosing Schedule for the Induction of Transitional Cell Carcinomas in Female F344 Rats With the Use of &lt;italic&gt;N&lt;/italic&gt;-Butyl-&lt;italic&gt;N&lt;/italic&gt;-(4-hydroxybutyl)nitrosamine&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: P J Becci, H J Thompson, C J Grubbs, R C Moon
Journal: JNCI Journal of the National Cancer Institute (1979)
Abstract 12830: Primary Prevention of Atrial Fibrillation With Angiontensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients of End-Stage Renal Disease- A Nationwide Cohort Study Using Insurance Claims Database
Authors: Ting-Tse Lin, Min-Tsun Liao, Lian-Yu Lin
Journal: Circulation (2014)

Background: Current evidence suggests that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARB) reduce the incidence of new atrial fibrillation (AF) in a variety of settings including the treatment of left ventricular dysfunction or hypertension. This study was to assess whether ACEIs and ARB could decrease incidence of AF in patients of end stage renal disease (ESRD). Materials and Methods: We identified all patients who developed ESRD through January 1998 to December 2008 from the National Health Insurance Research Database, Taiwan. The primary endpoint was new onset of AF and the median duration of follow up was 1499 days. The control group was patients not prescribing ACEIs or ARB. Hazard ration of both ACEIs vs. control and ARB vs. control were analyzed. Results: Among 102688 patients, 14926 (14.5%) were prescribed with ACEIs, 16282 (15.9) with ARB but 71480 (69.6%) were not prescribed ACEIs or ARB. Overall, patients treated with ACEIs (adjusted hazard ratio [HR] 0.587, 95% confidence interval [CI] 0.519-0.633, P&lt;0.001 ) or ARB (adjusted HR 0.542, 95% CI 0.461-0.637, P&lt;0.001 ) had a reduced incidence of AF. The preventive effect between two classes of drugs was favored ARB (P&lt;0.001). The longer patients taking ACEIs or ARB, the better prevention of AF are. The similar reduction of AF is also noted in stratified analysis of age, gender, hypertension, congestive heart failure and diabetes. Conclusion: Both ACEIs and ARB appear to be effective in the primary prevention of AF in ESRD patients. This analysis supports the concept of renin-angiotensin system inhibition as an emerging treatment for the primary prevention of AF.
372PD Reduction in nephrotoxicities using short hydration in chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies
Authors: M. Tanaka, H. Horinouchi, H. Shiraishi, K. Tsuruoka, K. Yoshida, K. Itahashi, T. Asao, S. Kitahara, Y. Goto, S. Kanda, Y. Fujiwara, H. Nokihara, N. Yamamoto, Y. Ohe
Journal: Annals of Oncology (2015)
Habitual Abortion Due to Insufficiency of the Internal Cervical Os
Authors: V. B. Green-Armytage, J. C. M. Browne
Journal: BMJ (1957)

POLIOENCEPHALITIS"necessary to study cases occurring in other seasons and at other places in order to settle this point. SummaryDuring the 1955 poliomyelitis epidemic 121 cases of clinically typical poliomyelitis were admitted to hospital.In the same period nine cases of encephalitis-like illness were seen.These were investigated by standard virological techniques, and seven were shown to be infected with poliomyelitis virus.The infected cases fell into two groups-those which resembled acute cerebellar ataxia, and those which resembled acute encephalitis.Probably poliomyelitis infection can occasionally manifest itself by symptoms exclusively related to cerebellar or " ence- phalitic" lesions.We are grateful to Drs.J.
Therapy for lymphoma in the elderly.
Authors: J E Radford, D H Vesole
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.7.981 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2738627 Therapy for lymphoma in the elderly. J E Radford JrxJ E Radford JrSearch for articles by this author , D H VesolexD H VesoleSearch for articles by this author https://doi.org/10.1200/JCO.1989.7.7.981 First Page PDF © 1989 by American Society of Clinical Oncology
Repeat Tdap Vaccination and Adverse Birth Outcomes
Authors: Yanmin Zhu, Sascha van Boemmel-Wegmann, Yasser Albogami
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II study of paclitaxel poliglumex (PPX) /carboplatin (C) for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma
Authors: T. Herzog, R. J. Barret, R. Edwards, F. B. Oldham
Journal: Journal of Clinical Oncology (2005)

5012 Background: C/paclitaxel (P) treatment, with a 70% complete response rate based on CA 125, is standard induction therapy for ovarian cancer. PPX (XYOTAX), a macromolecular drug conjugate that links P with a biodegradable polymer, poly-L-glutamic acid, is water soluble and can be administered as a 10 min infusion. Eliminating the need for CremophorEL reduces the risk of hypersensitivity reactions, even without premedication. The safety and efficacy of PPX/C for induction therapy followed by single agent PPX for maintenance therapy were evaluated. Methods: 82 patients (pts) with newly diagnosed stage III/IV ovarian or primary peritoneal carcinoma who had standard debulking surgery for their disease were enrolled. Pts received induction therapy of C (AUC 6) + 175 (62 pts) or 210 mg/m2 (20 pts) PPX as a 10 min IV infusion Q3 weeks. Pts with ≥stable disease after 4–6 cycles receive single-agent maintenance therapy (175 mg/m2 PPX, Q4 weeks X 12). NCI CTC (v 2) is used to assess safety. Response is based on CA 125 (Rustin Criteria) and RECIST. Results: 82 pts have completed induction treatment. Preliminary efficacy data are available for 67 pts, safety data for 28. Ages range from 38–83 years. Based on CA 125 levels, response rate after induction was 95% (54 CR, 10 PR). Grade 3 neuropathy occurred in 7/23 pts at 210 mg/m2 and resulted in withdrawal in 6 pts. As a result, the dose of PPX was reduced to 175 mg/m2 for subsequent patients. Grade 4 neuropathy has not been reported. No anaphylaxis occurred. Upon completion of maintenance therapy, time to progression, overall survival, and optimal maintenance dosing will be evaluated. Preliminary data suggest that a reduction in dose to avoid neuropathy may be required to allow completion of an 18 month treatment regimen. Conclusion: Treatment of pts with ovarian cancer with PPX/C produced a high response rate following surgical debulking. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Cell Therapeutics Cell Therapeutics
Pathogenesis of Feline Viral Fibrosarcomas: Dose and Age Effects 2
Authors: S. P. Snyder, D. L. Dungworth
Journal: JNCI Journal of the National Cancer Institute (1973)

The effects of virus dose and host age at the time of inoculation were studied in cats. Twenty-eight neonatal kittens were inoculated with tenfold serial dilutions of a pooled cell-free preparation of ST-feline sarcoma virus to examine the effects of virus dose on subsequent tumorigenesis. Similarly, age effects were studied in 20 cats ranging from neonates to 1-year-olds. Fibrosacromas induced in younger animals and in those given the higher doses of inoculum had shorter latent periods, enlarged rapidly, contained more virus particles on electron microscopy, attained greater size, and resulted in the animals' deaths. Conversely, older animals and those given lower doses of inoculum developed slowly enlarging tumors after a prolonged latent period; these fibrosarcomas contained fewer virus particles and tended to regress.
GENO-11PERIOSTIN MAINTAINS A MESENCHYMAL PROGRAM IN GLIOBLASTOMA STEM CELLS
Authors: Pascal Zinn, Markus Luedi, Sanjay Singh, Masumeh Hatami, Faramak Zandi, Eric Sulman, Frederick Lang, Rivka Colen
Journal: Neuro-Oncology (2015)

Our radiogenomic screen identified Periostin (POSTN) to be highly expressed in glioblastoma (GBM) with high edema/FLAIR. Subsequently, POSTN is implicated in glioblastoma invasion and recruitment of tumor associated macrophages. However, its impact on glioblastoma stem cells (GSC) biology/properties is largely unknown. Here GSC lines with high endogenous POSTN expression levels were used to generate inducible shRNA mediated loss of function (LOF) clones. GSCs with low/undetectable levels of POSTN expression were used to generate Gain of function (GOF) clones. In vitro tests were performed to assess the impact of POSTN LOF and GOF on GSC properties such as self-renewal, BrdU label retention, differentiation potential etc. We show that GSCs with POSTN LOF acquired an increased stem like state with unaltered proliferation rate. When these clones were implanted at orthotopic locations in mouse, POSTN LOF was associated with increased survival of mice. Cells of human origin were isolated from tumors using human specific HLA Class I ABC antibody by FACS. Total RNA from these sorted cells (without cell-culture) were used for expression profile analysis by HTA 2.0 array from affymetrix. Transcriptome analyses of POSTN LOF cells show inhibition of multiple mesenchymal associated networks such as CEBPB (a master regulator of mesenchymal program in GBM), PRDM1, TGFB1, FGF2, WNT3A, HIF1A etc. with concomitant activation of MYCN network, indicating a mesenchymal to proneural switch. We have generated POSTN and CEBPB dual knockdown clones and are currently investigating the molecular link between these two key mesenchymal genes in GSC context. Our results show that POSTN maintains a mesenchymal program in GSC by coopting with intracellular factors such as CEBPB. Therefore, neutralizing extracellular POSTN will have far reaching impact in terms of therapeutics where while blocking GBM invasion and it may simultaneously block a mesenchymal program in stem cell niche in GBM.
Clinical correlates of the deficit syndrome of schizophrenia
Authors: R W Buchanan, B Kirkpatrick, D W Heinrichs, W T Carpenter
Journal: American Journal of Psychiatry (1990)

The authors propose using primary and enduring negative or deficit symptoms for dichotomizing schizophrenic patients into two groups, deficit and nondeficit. The validity of this approach was examined by comparing 17 deficit and 17 nondeficit patients for differences in premorbid adjustment and degree of neurological impairment. Deficit patients were characterized by poorer premorbid adjustment and greater neurological impairment. Neurological impairment was not related to premorbid adjustment in either group or in the total patient population. These findings support the utility of deficit symptoms for defining a more homogeneous subgroup of schizophrenia.
Failing regimens should be modified with multiple drugs instituted simultaneously
Authors: J R Greig, I J Eltringham, K Birthistle
Journal: BMJ (1996)

The third child, a 2 year old who had had recur- rent chest symptoms for several months, was referred for surgery for a possible bronchogenic or duplication cyst diagnosed on computed tomogra- phy.Surgery was cancelled when a preoperative Mantoux test (1 U) yielded a positive result.None of the patients had a history of contact with some- one with tuberculosis.All were given standard antituberculous treatment and progressed well.
Anti-TNFalpha induced apoptosis contributes to the induction of autoantibodies but not the decrease of synovial inflammation in spondyloarthropathy (SpA)
Authors: Leen De Rycke, Tineke Cantaert, Bernard Vandooren, Elli Kruithof, Ca Wijbrandts, Filip De Keyser, Eric Veys, Pp Tak, Dominique Baeten
Journal: Annals of the Rheumatic Diseases (2007)
Epigenetic Alterations In Fanconi Anemia: Role In Disease Progression and Therapeutic Potential
Authors: Helio Belo, Gabriela Medeiros Silva, Bruno Cardoso, Beatriz Porto, José Barbot, Jorge Coutinho, Juan A Bueren, Jordi Surralles, Jose A Casado, Manuela Benedito, Hema Saturnino, Emília Costa, Maria Gomes Silva, Antonio Almeida
Journal: Blood (2013)
Survival of Human Cells in the Aggregate Form: Potential Index of In Vitro Cell Transformation2
Authors: Anton F. Steuer, Johng S. Rhim, Patricia M. Hentosh, Robert C. Ting
Journal: JNCI Journal of the National Cancer Institute (1977)

The ability of cell populations to survive in the aggregate form was compared to colony formation in soft agar and tumorigenicity in nude mice. Nontumorigenic human osteogenic sarcoma (HOS) cells, which formed colonies in soft agar, could not survive in the aggregate form. Tumorigenic HOS cell lines, which also formed colonies in soft agar, survived and proliferated in the aggregate form. Other cell types were tested with the same results. This approach, based on cell survival in the aggregate form, may provide an additional, reliable method for predicting the tumorigenic status of a cell population.
Anemia and Functional Disability in Older Adults With Cancer
Authors: Cynthia Owusu, Harvey Jay Cohen, Tao Feng, William Tew, Supriya G. Mohile, Heidi D. Klepin, Cary P. Gross, Ajeet Gajra, Stuart M. Lichtman, Arti Hurria
Journal: Journal of the National Comprehensive Cancer Network (2015)

Objectives: Anemia is associated with functional disability among older adults in general. However, the relationship between anemia and functional disability has not been well characterized among older adults with cancer. Therefore, we examined the association between anemia and functional disability in patients with cancer aged 65 years or older. Patients and Methods: We conducted cross-sectional analysis of data derived from a multicenter prospective study of 500 patients with cancer aged 65 years or older. The primary outcome was functional disability at chemotherapy initiation, defined as the need for assistance with at least one instrumental activity of daily living. Anemia (using WHO criteria) was defined as a hemoglobin (Hb) level of less than 12 g/dL in women and less than 13 g/dL in men. Multivariable logistic regression was used to examine the association between anemia and functional disability. Results: Among 491 evaluable patients (median age, 73.1 years [range, 65–91 years]), the prevalence of functional disability and anemia was 43% and 51%, respectively. Compared with patients without anemia, patients with anemia were more likely to report functional disability. On multivariable analysis, adjusting for sex, stage, and unintentional weight loss, patients with anemia were more likely to have functional disability (odds ratio, 2.40; 95% CI, 1.61–3.59). Conclusions: Anemia was highly prevalent and independently associated with functional disability in this cohort of older adults with cancer. Given the importance of functional status in cancer treatment decision-making, longitudinal studies evaluating the causal relation between anemia and functional status among older patients with cancer are warranted to evaluate causality.
Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis
Authors: Robert J. Arceci, Carl E. Allen, Ira Dunkel, Eric D. Jacobsen, James Whitlock, Robert Vassallo, Ivan M. Borrello, Allen Oliff, Shannon R. Morris, Beth Ann M Reedy, Alison Portnoy, Deborah A. Smith, Bob Noble, Amy A. Murnane, Stephen A. Szabo, Carlos Rodriguez-Galindo, Mark L. Heaney, Kenneth L. McClain, Sarah Vaseilbuh
Journal: Blood (2013)
Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma
Authors: D. Cunningham, S. Al-Batran, I. Davidenko, D. Ilson, A.M. Murad, N.C. Tebbutt, N. Baker, R. Jain, T. Hoang
Journal: Annals of Oncology (2014)
Measuring cervical length improves accuracy of estimating due date in late pregnancy, study shows
Authors: Susan Mayor
Journal: BMJ (2015)

A simple screening test of measuring cervical length using transvaginal ultrasound, currently used to detect women at high risk of premature labour, also improves the accuracy of predicting full term delivery dates in late pregnancy, a meta-analysis has found.

The study, reported in BJOG: An International Journal of Obstetrics and Gynaecology ,1 pooled data from five prospective studies assessing the accuracy of transvaginal ultrasound for …
Responsiveness to Chemotherapy of Mice With L1210 Lymphoid Leukemia Implanted in Various Anatomic Sites2
Authors: I. Wodinsky, P. C. Merker, J. M. Venditti
Journal: JNCI Journal of the National Cancer Institute (1977)

Eighteen anticancer agents were tested against the L1210 leukemia implanted into (BALB/c × DBA)F, mice iv, intracerebrally (ic), ip, sc, im, and intrathoracically (ith). Percentage increase in life-span (ILS) data showed that the responsiveness of tumor-bearing animals to chemotherapy depended on the anatomic location of the tumor. For weakly (30–59% ILS) active compounds (nitrogen mustard, actinomycin D, chlorambucil, hexamethylmelamine, 5-fluorodeoxyuridine, and procarbazine), only the iv or ip sites were responsive to treatment; for the moderately active (60–154% ILS) compounds (methotrexate, thio-TEPA, melphalan, 5-fluorouracil, hydroxyurea, and 5-azacytidine), the relative order of sensitivity of anatomic sites to chemotherapy was: iv>(ip and ith)>(im and sc)>ic. For highly active (≥155% ILS) compounds [Cytoxan, cytosine arabinoside, 1,3-cis(2-chloroethyl)-1-nitrosourea (CCNU), methyi-CCNU, isophosphamide, and 1,3- bis(2-chloroethyl)-1-nitrosourea), the relative order of sensitivity of anatomic sites was: (iv, sc, ith, and ip)>(ic and im). Experimental data indicated that the responses to weakly active compounds were more susceptible to change with the site of tumor implantation than were those of highly active compounds; the iv and ip sites were more critical for the detection of weakly active compounds than highly or moderately active compounds.
Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL
Authors: Panagiotis Baliakas, Anastasia Hadzidimitriou, Lesley-Ann Sutton, Davide Rossi, Eva Minga, Neus Villamor, Marta Larrayoz, Jana Kminkova, Andreas Agathangelidis, Zadie Davis, Eugen Tausch, Evangelia Stalika, Jitka Malcikova, Larry Mansouri, Lydia Scarfò, Diego Cortese, Karla Plevova, Karin Ekstrom Smedby, Gunnar Juliusson, Antonios M Makris, Alba Navarro, Julio Delgado, David Oscier, Chrysoula Belessi, Stephan Stilgenbauer, Paolo Ghia, Sarka Pospisilova, Gianluca Gaidano, Elias Campo, Kostas Stamatopoulos, Jonathan C Strefford, Richard Rosenquist
Journal: Blood (2013)